According to results from a recent phase II study, most patients with drug-resistant, true #extramedullary #myeloma responded to dual treatment with #talquetamab plus #teclistamab, with researchers observing a 61% PFS and 74% OS at 12 months: https://ow.ly/q6gI50YpblV #MMsm
#HemeSky #MedSky

The March issue is out now! Issue highlights include a feature on #AI in medical education, a look at POEMS syndrome, dual-targeting therapy in #extramedullary #myeloma, and more. Check out the full issue lineup here: https://ow.ly/57Ym50YoBJm
#HemeSky #MedSky

New hope for toughest myeloma through off-the-shelf immunotherapy – BioNews Central An off-the-shelf dual-antibody therapy can produce deep and durable responses in extramedullary multiple myeloma, one of the most aggressive and treatment-resistant forms of the disease. ...

An off-the-shelf #DualAntibodyTherapy can produce deep and durable responses in #extramedullary #MultipleMyeloma, one of the most aggressive and treatment-resistant forms of the disease.
#AntibodyTherapy #TreatmentResistance #MultipleMyelomaTreatment